Mauro Schechter

Active 1994–2025

54
Papers
20,004
Citations
50
h-index
51
i10-index

Citations

Citations per year for Mauro Schechter1988: 2 citations1995: 2 citations1996: 1 citations1997: 3 citations1998: 2 citations1999: 3 citations2000: 33 citations2001: 46 citations2002: 54 citations2003: 80 citations2004: 82 citations2005: 54 citations2006: 81 citations2007: 99 citations2008: 180 citations2009: 146 citations2010: 149 citations2011: 175 citations2012: 161 citations2013: 160 citations2014: 174 citations2015: 183 citations2016: 202 citations2017: 149 citations2018: 156 citations2019: 666 citations2020: 516 citations2021: 392 citations2022: 276 citations2023: 184 citations2024: 345 citations2025: 115 citations2026: 2 citations1989–1994: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,613 citing papers, 32.8% of this breakdownUnited Kingdom: 586 citing papers, 7.4% of this breakdownSouth Africa: 454 citing papers, 5.7% of this breakdownCanada: 319 citing papers, 4% of this breakdownFrance: 266 citing papers, 3.3% of this breakdownSwitzerland: 238 citing papers, 3% of this breakdownAustralia: 205 citing papers, 2.6% of this breakdownUganda: 189 citing papers, 2.4% of this breakdownNetherlands: 185 citing papers, 2.3% of this breakdownBrazil: 183 citing papers, 2.3% of this breakdownSpain: 182 citing papers, 2.3% of this breakdownChina: 180 citing papers, 2.3% of this breakdown
0%32.8%Other 29.6%

Fields

  • Medicine74.9%
  • Immunology and Microbiology16%
  • Biochemistry, Genetics and Molecular Biology2.6%
  • Health Professions1.5%
  • Psychology1.5%
  • Social Sciences1.4%
  • Other2.1%

Topics

  • HIV/AIDS Research and Interventions22.8%
  • HIV Research and Treatment12.2%
  • HIV/AIDS drug development and treatment10.8%
  • HIV, Drug Use, Sexual Risk7.9%
  • HIV-related health complications and treatments5.8%
  • Sex work and related issues4.5%
  • Other36%

Coauthors

All papers

Open in search
  1. Mpox in people with advanced HIV infection: a global case series

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Patricia Fernández Pardal, María Inés Figueroa, Pedro Cahn, Katharina Grabmeier‐Pfistershammer, Agnès Libois, Laurens Liesenborghs, Beatriz Grinsztejn, Mauro Schechter, Alberto dos Santos de Lemos, Alvaro Furtado Costa, Simone Queiroz Rocha, José Valdez Madruga, Darrell H. S. Tan, Sharmistha Mishra, Shreya Shah, Camila Jorquera, Alberto Castillo, Mauricio Carrión, Nelson Cevallos, Romain Palich, Valérie Pourcher, Emma Rubenstein, Pascal Migaud, Christoph Boesecke, Christian Hoffmann, Konstantinos Protopapas, Silvia Nozza, Anna Maria Cattelan, Cristina Mussini, Antonella d’Arminio Monforte, Raúl Adrian Cruz Flores, Edgar Pérez‐Barragán, Alma Leticia Rodríguez Guzmán, Dimie Ogoina, Nneka Marian Chika-Igwenyi, Onyeaghala Chizaram, Jenny Valverde López, Angelica García Tello, María Ubals, Martí Vall, Adrià Mendoza, Clara Suñer, Bonaventura Clotet, Jordi Bechini, José Antonio Lepe, Ma Dolores Navarro-Amuedo, José I Bernadino, Alba Català, Eloy José Tarín Vicente, Borja González Rodríguez, Sergi Rodríguez-Mercader, Francisca Sánchez-Martinez, Esperanza Cañas‐Ruano, Laura Parra‐Navarro, Finn Filén, Carmen Tallón de Lara, Dominique L. Braun, Vanja Piezzi, Michael Burkhard, Helen Kovari, Anja Mönch, Jake Dunning, Pedro Simoes, Achyuta Nori, Sarah S. Keegan, John Thornhill, Vanessa Apea, Teymur Noori, Joyce Jones, Seth D. Judson and 9 more - The Lancet 2023 cited by 485

  2. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James F. Rooney, Howard S. Jaffe, Ana I. Martínez, David Burns, David V. Glidden - New England Journal of Medicine 2010 cited by 5,133

  3. Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter Piot, Anton Pozniak, Thomas C. Quinn, Jürgen K. Rockstroh, Jirair Ratevosian, Owen Ryan, Serra Sippel, Bruno Spire, Agnès Soucat, Ann Starrs, Steffanie A. Strathdee, Nicholas M. Thomson, Stefano Vella, Mauro Schechter, Peter Vickerman, Brian W. Weir, Chris Beyrer - The Lancet 2018 cited by 761

  4. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , - The Lancet Infectious Diseases 2014 cited by 1,250

  5. Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men

    Authors: , , , , , , , , , , , , , , , , , - Science Translational Medicine 2012 cited by 1,043

  6. HIV-1 DNA predicts disease progression and post-treatment virological control

    Authors: , , , , , , , , , , , , , , , , , , - eLife 2014 cited by 307

  7. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs

    Authors: , , , , - The Lancet 2010 cited by 507

  8. Modeling the Slow CD4+ T Cell Decline in HIV-Infected Individuals

    Authors: , , , - PLoS Computational Biology, PLoS Comput. Biol. 2015 cited by 72

  9. Immunological biomarkers predict HIV-1 viral rebound after treatment interruption

    Authors: , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2015 cited by 178

  10. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials

    Authors: , , , , , , , , , , , , , , , - Vaccine 2009 cited by 276

  11. Community-Based Interventions to Improve and Sustain Antiretroviral Therapy Adherence, Retention in HIV Care and Clinical Outcomes in Low- and Middle-Income Countries for Achieving the UNAIDS 90-90-90 Targets

    Authors: , , , , , , , , , , , , , , , - Current HIV/AIDS Reports 2016 cited by 185

  12. Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil

    Authors: , , , , , , , , , - BMC Infectious Diseases 2023 cited by 34

  13. HIV-Related Stigma, Isolation, Discrimination, and Serostatus Disclosure

    Authors: , , , , , , , - Journal of the International Association of Physicians in AIDS Care 2012 cited by 161

  14. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial

    Authors: , , , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2015 cited by 150

  15. Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme

    Authors: , , , , , , , - International Journal of Epidemiology 2007 cited by 141

  16. Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial

    Authors: , , , , , , , , , , , , , , - Open Forum Infectious Diseases 2017 cited by 87

  17. Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine

    Authors: , , , , , , , , , , - Clinical Infectious Diseases 2018 cited by 77

  18. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries

    Authors: , , , , , , , , , , , , , , - The Lancet 2006 cited by 1,107

  19. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population

    Authors: , , , , , , , , , - AIDS 2012 cited by 371

  20. Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy

    Authors: , , , , , , , , , , , , - PLoS ONE 2013 cited by 93

  21. Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2008 cited by 507

  22. Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1

    Authors: , , , , , , , , , , , , , , , - PLoS Medicine 2004 cited by 276

  23. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis

    Authors: , , , , , , , , , , , , , , - AIDS 2014 cited by 142

  24. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities

    Authors: , , - Current Opinion in HIV and AIDS 2009 cited by 139